A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting

Bristol-Myers Squibb177 enrolled

Overview

This is a prospective, non-interventional study conducted in CP-CML patients receiving dasatinib who are enrolled by a sample of hematologists in France.

Study Type

OBSERVATIONAL

Enrollment

177

Conditions

Chronic Myeloid Leukemia

Interventions

Non-InterventionalOTHER

Non-Interventional

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged greater than or equal to 18 years * Patients diagnosed with CP-CML * Patients who started dasatinib within the last month before inclusion, or on the day of inclusion or within the month after inclusion Exclusion Criteria: * Patients participating in an ongoing interventional trial * Patients diagnosed with AP-CML (accelerated phase) or BP-CML (blast phase)

Locations (1)

Local Institution

Paris, France

Outcomes

Primary Outcomes

Incidence of CP-CML patients remaining on dasatinib treatment

Time frame: 24 months

Secondary Outcomes

Distribution of median age of CP-CML patients receiving dasatinib

Time frame: 24 months

Distribution of sex ratio of CP-CML patients receiving dasatinib

Time frame: 24 months

Distribution of concomitant treatment of CP-CML patients receiving dasatinib

Time frame: 24 months

Distribution of cardiovascular risk factors of CP-CML patients receiving dasatinib

Time frame: 24 months

Distribution of body mass index (BMI) of CP-CML patients receiving dasatinib

Time frame: 24 months

Distribution of comorbidities of CP-CML patients receiving dasatinib

Time frame: 24 months

Distribution of disease characteristics duration between diagnosis and drug initiation in CP-CML patients receiving dasatinib

Time frame: 24 months

Distribution disease characteristics of last known molecular response in CP-CML patients receiving dasatinib

Time frame: 24 months

SOKAL distribution of disease characteristics of CP-CML patients receiving dasatinib

Time frame: 24 months

Distribution of prior treatment(s) of CP-CML patients receiving dasatinib

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.